膀胱癌组织中MDR1基因产物P-GP_(170)、GST-π和TOPOⅡ的表达及意义  

Expression of P-GP_(170)、glutathiones transferases-π (GST-π) and topoisomeraseⅡ(TOPOⅡ) in the tissue of bladder carcinoma

作　　者：魏若晶[1] 贾宁[1] 杨文增[1] 周洪月[1] 赵春利[1] 张彦桥[1] 

机构地区：[1]河北大学附属医院泌尿外科,河北保定071000

出　　处：《医学研究与教育》2010年第1期7-10,共4页Medical Research and Education

摘　　要：目的研究膀胱癌组织中MDR1基因产物P-GP170、GST-π(glutathiones transferases-π)和TOPOⅡ(topoisomeraseⅡ,TOPOⅡ)的表达与生物学行为之间的关系。方法应用免疫组织化学方法研究72例膀胱癌组织中P-GP170、GST-π和TOPOⅡ的表达。结果P-GP170的单独表达率69.4%(50/72)。在Ⅰ级23例中表达率52.2%(12/23);在Ⅱ级21例中表达率71.4%(15/21);在Ⅲ级28例中表达率82.1%(23/28)。56例初发膀胱癌中阳性表达率62.5%(35/56);16例羟喜树碱膀胱内灌注化疗失败的复发膀胱癌阳性表达率93.7%(15/16)。表明P-GP170的表达水平与膀胱癌的恶性行为及病理分级密切相关(P<0.05)。GST-π的单独表达率58.3%(42/72)。在Ⅰ级23例中表达率43.8%(10/23);在Ⅱ级21例中表达率57.1%(12/21);在Ⅲ级28例中表达率71.4%(20/28)。56例初发膀胱癌中阳性表达率48.2%(27/56);16例羟喜树碱膀胱内灌注化疗失败的复发膀胱癌阳性表达率93.7%(15/16)。表明GST-π的表达水平与膀胱癌的恶性行为及病理分级密切相关(P<0.05)。TOPOⅡ的单独表达率52.8%(38/72)。在Ⅰ级23例中表达率73.9%(17/23);在Ⅱ级21例中表达率47.6%(10/21);在Ⅲ级28例中表达率39.3%(11/28)。56例初发膀胱癌中阳性表达率60.7%(34/56);16例羟喜树碱膀胱内灌注化疗失败的复发膀胱癌阳性表达率25%(4/16)。表明TOPOⅡ的表达水平与膀胱癌的恶性行为及病理分级呈负相关(P<0.05)。P-GP170、GST-π和TOPOⅡ表达的相关性:P-GP170和GST-π同时表达率36.1%;P-GP170和TOPOⅡ同时表达率31.9%;GST-π和TOPOⅡ同时表达率29.1%;P-GP170、GST-π和TOPOⅡ同时表达率22.2%。结论P-GP170和GST-π阳性产物呈棕色颗粒,主要定位于肿瘤细胞膜和/或胞质;TOPOⅡ阳性产物主要定位于胞核。P-GP170、GST-π和TOPOⅡ的表达与膀胱癌的恶性行为及病理分级密切相关。膀胱癌组织中MDR1基因产物P-GP170和GST-π、TOPOⅡ的表达对肿瘤多药耐药起重要作用,并且多因素联合作用可能是MDR的主Objective To study bladder cancer MDR1 gene product P-GP170,GST-π （glutathiones transferases-π）and TOPO Ⅱ（topoisomerase Ⅱ,TOPO Ⅱ）expression and biological behavior relationship.Methods P-GP170,GST-π and TOPO Ⅱ expression of 72 cases of bladder cancer tissue were studied with immunohistochemical methods.Results P-GP170 expression in a separate was 69.4%（50/72）.In the 23 cases of grade Ⅰ expression rate was 52.2%（12/23）;in 21 cases of grade Ⅱ expression rate was 71.4%（15/21）;in 28 cases of grade Ⅲ expression rate was 82.1%（23/28）.56 cases of in primary bladder cancer positive expression rate was 62.5%（35/56）,16 cases of hydroxycamptothecin intravesical recurrence of bladder cancer chemotherapy positive expression rate was 93.7%（15/16）.The results showed that the expression level of P-GP170 bladder cancer,malignant behavior and was closely related to pathological grade （P 0.05）.GST-π expression in a separate was 58.3%（42/72）.In the 23 cases of grade Ⅰ expression rate was 43.8%（10/23）;in 21 cases of grade Ⅱ expression rate was 57.1%（12/21）;28 cases in grade Ⅲ expression rate was 71.4%（20/28）.56 cases of primary bladder cancer positive expression rate was 48.2%（27/56）,16 cases of hydroxycamptothecin intravesical recurrence of bladder cancer chemotherapy positive expression rate was 93.7%（15/16）.The level of GST-π expression in bladder cancer,malignant behavior and were closely related to pathological grade（P0.05）.TOPO Ⅱ individual expression was 52.8%（38/72）.In the 23 cases of grade Ⅰ expression rate was 73.9%（17/23）;in 21 cases of grade Ⅱ expression rate was 47.6%（10/21）;in 28 cases of grade Ⅲ expression rate was 39.3% （11/28）.56 cases of in primary bladder cancer positive expression rate was 60.7%（34/56）,16 cases of hydroxycamptothecin intravesical recurrence of bladder cancer chemotherapy positive expression rate was 25%（4/16）.TOPO Ⅱ showed that the expression level in the malignant behavior of

关 键 词：膀胱肿瘤 P-GP170 GST-Π TOPOⅡ 预后 

分 类 号：R737.14[医药卫生—肿瘤]